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substitutions resulting in splice mutations (N = 10), small deletions
(N = 20), small insertions (N = 6), gross deletion or gross insertion
(N = 2). The missense mutations we describe here, D149N and
S916Y, have not been described previously. They affect regions of the
protein that encode b strand and transmembrane domains, which
have been shown to be highly conserved during evolution, as all
known SERCA2 proteins from different species exhibit 100%
identity in these domains. The D149N and S916Y mutations may
alter the function of these important SERCA2 domains and, as a
consequence, impair cell adhesion and differentiation of epidermis.
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Epidermolysis Bullosa Carrier Frequencies in the US
Population
To the Editor:
Epidermolysis bullosa (EB) is a group of heritable blistering
disorders in which three major subtypes have been recognized on
the basis of clinical, genetic, and ultrastructural features: the simplex
(EBS: OMIM 601001, 131800, 131900, 131950, 131760),
junctional (JEB: OMIM 226700, 226650, 226730), and dystrophic
(DEB: OMIM 226600, 131705, 131850, 131750, 132000) forms
(Fine et al, 2000). Our laboratory has been involved in the
elucidation of the genes and mutations causing two of the major
subtypes, JEB and DEB, and has been performing genetic analysis
of patients and their families over the last several years (Pulkkinen
and Uitto, 1999). During the course of these studies we are
frequently consulted about families with an affected child as to the
recurrence risk and the type of genetic testing available. Frequently,
siblings and other family members become involved and are
concerned about their carrier status and their risk of having affected
children. Through these inquiries, it has come to our attention that
there is no published estimate of the population carrier risk of each
of the three forms of EB. Recent information compiled by the
National EB Registry (NEBR) (Fine et al, 1999) estimates the
incidence of each form of EB in the US population. From these
data population carrier frequencies can be calculated assuming
Hardy±Weinberg equilibrium. The data in Table I indicate the
results of these calculations using the incidence data presented by
Fine et al (1999). Since both dominant and recessive forms of EBS
and DEB are recognized, some caution must be exercised in
interpreting the data. Until mutation analysis has proven otherwise,
inheritance pattern is generally inferred from the pedigree. EBS,
usually autosomal dominant, may manifest with relatively mild
phenotype, which is elucidated only upon close examination and
questioning of the patient and his/her family. Alternately, EBS may
manifest with a much more severe phenotype, which is usually
identi®ed in the neonatal period. In addition, a few cases of
recessively inherited EBS have been described (Chan et al, 1994;
Rugg et al, 1994; Jonkman et al, 1996), which may be more severe
than most dominant cases, although the EBS phenotype may not be
a good predictor of inheritance pattern. Based on this information,
the majority of EBS cases may be considered to have a dominant
inheritance pattern. Similarly, dominant DEB is generally milder
than the recessive forms of dystrophic EB, particularly the
Hallopeau-Siemens type; however, a number of cases in which
mutations have been identi®ed by this laboratory (Christiano et al,
1996; JaÈrvikallio et al, 1997) and others (Gardella et al, 1996; Tamai
et al, 1999) indicate that milder forms of recessive dystrophic EB are
not uncommon, and these cases, in the absence of family history,
are clinically indistinguishable from mild, de novo dominantly
inherited DEB. On the other hand, dominant DEB cases are more
Table I. Carrier frequency of major EB subtypes in the US population
EB type Incidence per 106 Prevalence per 106 Carrier frequencya Carrier frequency as fraction
EB simplex 10.75 4.6 10.75 3 10±6
Junctional EB
All 2.04 0.44 2.86 3 10±3 1/333
Herlitz 0.41 0.07 1.28 3 10±3 1/781
Dystrophic EB
Dominant 2.86 0.99 2.86 3 10±6
Recessive 2.04 0.92 2.86 3 10±3 1/345
Unknown 0.82 0.47 1.81 3 10±3 1/556
aFor dominant disorders the carrier frequency is quoted as incidence in US population.
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numerous and have been generally inferred from the pedigree,
giving rise to the dominant and recessive incidence values (Fine
et al, 1999).
The new mutation rate for any of the forms of EB has not been
calculated; however, a number of sporadic cases of DEB have been
analyzed for mutations in the COL7A1 gene and are presumed to
result from germline mosaicism (Rouan et al, 1998; Hashimoto et al,
1999; Lee et al 2000). Continued elucidation of the mutations
involved in all forms of EB will allow us to further understand the
relative numbers of new mutations, and to correlate type of
mutation and pattern of inheritance.
The carrier incidence information provided in Table I should
enable genetics professionals to accurately calculate the risk of
recurrence to individual family members based on the family
history and provide up-to-date risk estimates that will facilitate
accurate counselling of extended families at risk.
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A Peripheral Blood T Cell Clone is a Prognostic Marker in
Mycosis Fungoides
To the Editor:
Dr Muche and colleagues (2000) have raised several criticisms of
our recent article (Fraser-Andrews et al, 2000). Speci®cally they
question our ®ndings that a peripheral blood T cell clone is an
independent prognostic feature in mycosis fungoides (p = 0.03 with
a hazards ratio of 2.6 after adjusting for age, skin stage, and lymph
node stage). Our results are based on multivariate analysis of 66
patients with up to 10 y follow-up and crucially includes analysis of
data at diagnosis for the majority of patients. Whilst we acknow-
ledge that further prospective studies of larger numbers with longer
follow-up are required, their comment that ``the survival or time to
progression in stage of the reported mycosis fungoides (MF)
patients with or without periphreal blood T cell clonality'' is not
relevant if data are analyzed from diagnosis. In other words the
results at diagnosis give a measure of tumor burden that can then be
entered into a multivariate analysis. The reason for the authors
differing conclusions is because their study is not based on data at
the time of diagnosis and predominanlty consists of patients with
T1 and T2 MF and only four patients with T3 stage disease. In
addition the follow-up in their study is much shorter than ours.
They state that the presence of a peripheral blood T-cell clone
¯uctuated during the course of the disease in some of their patients,
which would be expected and might re¯ect a partial response to
different therapies. Once again this emphasises the importance of
analysing data from diagnosis. Inevitably they cannot perform a
multivariate analysis on these results and therefore cannot make any
conclusoins regarding the prognostic implications.
We agree that the proportion of peripheral blood T cell clones
detected will re¯ect the sensitivity of the method and certainly the
use of oligonucleotides for the tumor speci®c V(D)J clonal TCR
gene rearrangement would be too sensitive. Intriguingly the
relative proporitons of their T1/T2 patients with preipheral blood
T cell clones are similar to our ®ndings in early stage disease. This
suggests that the sensitivity of the two techniques are broadly
similar, which would be expected given that both methods depend
on distinguishing clonal rearrangements on the basis of sequence
and size. In fact our method employed monoplex rather than
multiplex polymerase chain reaction and radioactively labelled
products which should increase the sensitivity. There is certainly no
basis for the authors contention that our approach is less sensitive
but comparative studies would be worthwhile.
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